AcquisitionOct 13, 2026Completed
🇺🇸 United States
VTVelaris Therapeutics, Inc.ATAlaunos Therapeutics, Inc.
Healthcare › Biotechnology
Deal valueUndisclosed
AnnouncedOct 13, 2026
ConsiderationUndisclosed
StructureNot stated
RegionNorth America
Cross-borderNo
Contingent paymentNo
Overview
Alaunos Therapeutics, Inc. agreed to acquire Velaris Therapeutics, Inc., a privately held biotechnology company developing ActRII-Fc ligand traps and complementary biologics for pulmonary arterial hypertension and related cardiopulmonary diseases. The acquisition consideration was not disclosed.
Deal rationale
The acquisition gives Alaunos a portfolio of ActRII-Fc ligand traps and complementary biologics targeting signaling imbalances that drive pulmonary vascular remodeling, positioning the company to deliver multiple proof-of-concept datasets.
AI-generated from the SEC filingCompletedHealthcare › BiotechnologyUnited StatesNorth America
Timeline
Valuation and terms
| Equity value | Undisclosed | |
|---|---|---|
| Enterprise value | Undisclosed | |
| Consideration | Undisclosed |
Advisors
Buy-side
CFCantor Fitzgerald
Sell-side
None listed
Parties
Target
VTVelaris Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —
Acquirer
ATAlaunos Therapeutics, Inc.
- Headquarters
- United States
- Ticker
- —